[Federal Register Volume 81, Number 175 (Friday, September 9, 2016)]
[Notices]
[Pages 62514-62515]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-21699]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION: Technology description follows.
Reagent for Mapping Genome-Wide Enhancer-Promoter Interactions
    This invention is a research reagent named the ``bivalent Tn5 
complex'' used in transposition-mediated analysis of chromatin looping 
(TrAC-looping) to determine genome-wide enhancer-promoter interactions 
during studies of 4D nucleomes in normal development and disease 
conditions. Enhancer-promoter interactions are key in temporospatial 
control of gene expression during normal development and pathological 
conditions. Currently available methods of analyzing genome-wide 
enhancer-promoter interactions are insufficient in achieving necessary 
resolution, give rise to false positive artifacts due to in vitro 
ligation steps, or too expensive due to the necessity of sequencing 
over a billion reads. The instant reagent and associated TrAC-looping 
technique effectively reduce false positive detection and achieve a 10 
to 100-times higher resolution at lower cost for mapping genome-wide 
interactions between enhancers and promotes essential for the control 
of gene expression in normal development and pathological conditions.

References

--Lieberman-Aiden E et al., Science 2009 Oct 9;326(5950):289-93.

[[Page 62515]]

--Rao S et al., Cell. 2014 Dec 18;159(7):1665-80.
--Goryshin et al., JBC 1998 March 273(13) 7367-7374.

Potential Commercial Applications

--Genome wide Enhancer-Promoter mapping
--Functional annotation of genomic structure
--Three-dimensional chromatin organization
--Analysis of 4D Nucleomes during development of diseases
--Identification of key genomic sequences involved in diseases
--Diagnostic for diseases associated with aberrant gene expression

Competitive Advantages

--Transposition mediated analysis of chromatin looping

    Development Stage: Research reagent.
    Inventors: Keji Zhao and Qingsong Tang (both of NHLBI).
    Intellectual Property: HHS Reference No. E-266-2016/0;--Research 
reagent.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: September 2, 2016.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2016-21699 Filed 9-8-16; 8:45 am]
 BILLING CODE 4140-01-P